Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Results from this international, phase 2 trial of the CAR T-cell therapy tisagenlecleucel demonstrated high rates of durable responses in adult patients with relapsed/refractory diffuse large B-cell lymphoma, but not without adverse events (AEs). The most common any-grade AEs included cytokine release syndrome (CRS; 58%), anemia (48%), pyrexia (35%), decreased neutrophil count (34%), decreased platelet count (33%), decreased white-cell count (33%), and diarrhea (32%). Additionally, 21% of patients experienced neurologic AEs with eight weeks of infusion. Treatment options for CRS algorithms include tocilizumab and glucocorticoids.

New England Journal of Medicine